|
Affiliation |
Hospital Pediatrics |
Graduating School 【 display / non-display 】
-
-1992.03
Akita University Faculty of Medicine Graduated
Graduate School 【 display / non-display 】
-
-1997.03
Akita University Graduate School,Division of Medicine Doctor's Course Completed
Campus Career 【 display / non-display 】
-
2009.06-Now
Akita University Hospital Pediatrics Lecturer
Research Achievements 【 display / non-display 】
-
Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.
Wolthers, B.O.他
Lancet Oncology 18 1238 - 1248 2017.07 [Refereed]
Research paper (journal) Domestic Co-author
-
Management of tumor lysis syndrome in pediatric patients with leukemia: A survey in Japan
Kakazu Mariko, Osone Shinya, Shinoda Kunihiro, Yano Michihiro, Sano Hirozumi, Shinkoda Yuichi, Mori Naoko, Kato Yoko, Adachi Souichi, Fukushima Keitaro
The Japanese Journal of Pediatric Hematology / Oncology ( The Japanese Society of Pediatric Hematology / Oncology ) 60 ( 2 ) 143 - 148 2023
<p>Background: Tumor lysis syndrome (TLS) is a potentially fatal complication associated with the treatment of childhood leukemia. A practical guideline by the Japanese Society of Pediatric Hematology/Oncology in 2016 indicates the standard therapy for TLS; it does not recommend urinary alkalization as a premise for the use of rasburicase. However, the current situation regarding supportive care for patients with TLS has not been clarified in Japan. Therefore, we conducted a nationwide survey of the institutions participating in the Japanese Pediatric Leukemia/Lymphoma Study Group.</p><p>Method: From February to June 2016, we conducted a web survey of practitioners at 155 facilities using SurveyMonkey<sup>®</sup>.</p><p>Results: We received valid responses from 99 facilities (64%). Urinary alkalinization was performed at initiation of induction therapy in 54% of the institutions, and it was conducted in 67% of the facilities where five or fewer new hematopoietic tumors were reported per year. Uric acid production inhibitors were administered prophylactically in 75% of the facilities. Rasburicase was used in most institutions to treat TLS with an average continuous duration of 5.4 days. Regarding the re-administration of rasburicase, 45% of the respondents reported no adverse effects; however, data from the period between the initial administration and re-administration were not investigated.</p><p>Conclusions: This survey showed that rasburicase was widely used for the prevention and treatment of TLS, but that 54% of the institutions utilized urinary alkalinization. It is important that TLS is appropriately managed in all childhood cancer treatment facilities in the rasburicase era.</p>
-
Current status of procedural sedation and analgesia for pediatric cancer patients in Japan: A report from the JCCG (Japan Children's Cancer Group)
Shinkoda Yuichi, Kato Yoko, Mori Naoko, Osone Shinya, Kakazu Mariko, Sano Hirozumi, Shinoda Kunihiro, Yano Michihiro, Ishida Yuji, Saito Yuya, Sawada Akihisa, Toyoda Hidemi, Sakaguchi Kimiyoshi, Adachi Souichi, Fukushima Keitaro
The Japanese Journal of Pediatric Hematology / Oncology ( The Japanese Society of Pediatric Hematology / Oncology ) 59 ( 5 ) 400 - 406 2022
<p>Background: A nationwide survey was conducted by the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG: current JCCG) Supportive Care Committee to determine the current status of procedural sedation and analgesia for pediatric patients with cancer and to clarify issues encountered in such procedures.</p><p>Methods: A cross-sectional investigation at 155 institutions that are members of the JPLSG was conducted between October 2015 and March 2016 through a web survey (SurveyMonkey<sup>®</sup>) to gather institutional information and details concerning procedural sedation and analgesia for pediatric patients with cancer.</p><p>Results: Valid responses were obtained from 89 (57%) institutions. Only 27% of the institutions had child life specialists (CLSs) and hospital play specialists (HPSs). Psychological preparation was routinely provided by 36% of the institutions prior to the procedures and treatments. The most common procedural sedation and analgesia medications used were oral triclofos for echocardiography and computed tomography, intravenous thiopental and thiamylal for magnetic resonance imaging and radiotherapy, intravenous midazolam and ketamine for lumbar puncture, bone marrow aspiration, and biopsy, and inhalational anesthetics in the operating room for central venous catheter (CVC) insertion. Sedation and pain management, except for CVC insertion, were performed by attending pediatricians in approximately 90% of cases.</p><p>Conclusions: Procedural sedation and analgesia were actively performed for pediatric cancer patients with the burden placed heavily on attending physicians. Therefore, inclusion of more CLSs and HPSs involved in pediatric cancer care is necessary to optimize procedural sedation and analgesia.</p>
-
Sano Hirozumi, Fukushima Keitaro, Yano Michihiro, Kakazu Mariko, Shinoda Kunihiro, Kato Yoko, Shinkoda Yuichi, Mori Naoko, Ishida Yuji, Saito Yuya, Toyoda Hidemi, Adachi Souichi, Osone Shinya
The Japanese Journal of Pediatric Hematology / Oncology ( The Japanese Society of Pediatric Hematology / Oncology ) 59 ( 3 ) 275 - 280 2022
<p>Background: There is only limited information currently available on the types of central venous catheter (CVC) used and how they are managed nationwide during the long-term treatment of childhood leukemia/lymphoma. Therefore, we investigated the selection and management of CVCs at institutions participating in the Japan Pediatric Leukemia/Lymphoma Study Group (JPLSG).</p><p>Method: Between February 2016 and July 2016, the JPLSG Supportive Care Committee conducted a web questionnaire survey using SurveyMonkey<sup>®</sup> on the use and management of CVCs at 155 institutions participating in JPLSG.</p><p>Results: Responses were received from 98 institutions (63%). In the following, “%" refers to the response ratio based on the number of facilities that responded. Regarding children with leukemia/lymphoma, 97% of institutions answered that they used CVCs for all cases. Regarding the type of CVC, 86% of institutions used long-term indwelling types, 16% short-term indwelling types, 7% ports, and 44% peripherally inserted types. Differences were observed in the management of skin puncture sites and the infusion line, including the access port, and suspected catheter-related bloodstream infections among institutions.</p><p>Discussion: Owing to differences in the scale of institutions and the medical care system, the management of CVCs markedly differed among institutions. On the basis of the results of this survey, we plan to develop a guide for the management of CVCs.</p>
-
Suzuki Koji, Saito Yuya, Sano Hirozumi, Sawada Akihisa, Shinkoda Yuichi, Mori Naoko, Fukuzawa Masahiro, Fukushima Keitaro, Yamamoto Nobuyuki, Shinoda Kunihiro, Yano Michihiro, Ishida Yuji, Osone Shinya, Kakazu Mariko, Kato Yoko
The Japanese Journal of Pediatric Hematology / Oncology ( The Japanese Society of Pediatric Hematology / Oncology ) 58 ( 2 ) 175 - 181 2021
<p>Purpose: To provide guidance regarding dietary and nutritional management practices in pediatric cancer in Japan, a nationwide survey was conducted to understand the current situation.</p><p>Method: From April to July 2017, the Supportive Care Committee of the Japan Children's Cancer Group (JCCG) surveyed 153 institutions regarding dietary and nutritional management protocols, using the Survey Monkey<sup>®</sup> Web survey system.</p><p>Results: Of the 153 institutions contacted, 110 institutions (72%) and 112 clinical departments (106 internal medicine departments and 6 surgical departments) returned valid responses. Dietary restrictions during chemotherapy were performed in 47% and 46% of departments "at the start of chemotherapy" and "at the time when neutrophils <500/μL", respectively. Nonhospital food was conditionally allowed by 90% of all departments. Most departments restricted nonheated foods, but whether the physicians permitted the consumption of milk, fermented beverages, sealed side dishes, lunch boxes, and home cooking varied among departments. Approximately 40% of all departments reported that all patients received nutritional support from dietitians or a nutritional support team.</p><p>Discussion: This survey revealed that dietary and nutritional management protocols for patients with childhood cancer were inconsistent among various health institutions in Japan. In the future, we would like to provide guidance that can be shared among all participating JCCG facilities.</p>
-
Kato Yoko, Saito Yuya, Sawada Akihisa, Toyoda Hidemi, Adachi Souichi, Fukushima Keitaro, Mori Naoko, Shinkoda Yuichi, Osone Shinya, Kakazu Mariko, Sano Hirozumi, Shinoda Kunihiro, Yano Michihiro, Ishida Yuji
The Japanese Journal of Pediatric Hematology / Oncology ( The Japanese Society of Pediatric Hematology / Oncology ) 57 ( 2 ) 178 - 184 2020
<p>Background: Pharmacological pain management issues in pediatric cancer patients in Japan have not been identified.</p><p>Methods: A cross-sectional investigation at 155 institutions belonging to the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) was conducted between October 2015 and March 2016 by web survey, addressing pharmacological pain management issues in each institutional policy.</p><p>Results: The eligible responses were obtained from 81 institutions (response rate, 52%). Among these institutions, 98% provided pain management by pediatric oncologists, and 37% were aware of and implemented the World Health Organization (WHO) guidelines published in 2012. The first choice of analgesics for mild pain was oral acetaminophen. For more-than-moderate pain, low-dose strong opioids or pentazocine were used at some institutions. Immediate-release oral morphine and transdermal fentanyl were the first choices among strong opioids in cases without blood access in 48% and 47% of institutions, respectively. On the other hand, intravenous morphine and intravenous fentanyl were the first choices in cases with blood access in 80% and 68% of institutions, respectively. Pregabalin was administered for neuropathic pain. Steroid was administered for bone pain. Radiation therapy and nerve block were also performed at 36% and 7% institutions, respectively.</p><p>Conclusions: Pediatric oncologists were the main providers of pharmacological pain management. Although some off-label analgesics and adjuvants, as well as radiation therapy and nerve block are not mentioned in the guidelines, they were actually used in some hospitals. These should be carefully investigated for indications, proper use, efficacy, and safety.</p>